• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病:解决拉丁美洲公共卫生问题的挑战与机遇。

NAFLD: Challenges and opportunities to address the public health problem in Latin America.

机构信息

Departamento de Gastroenterología, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Chile.

Unidad de Trasplante Hepático, Servicio de Hepatología, Hospital Privado de Rosario, Rosario, Argentina.

出版信息

Ann Hepatol. 2021 Sep-Oct;24:100359. doi: 10.1016/j.aohep.2021.100359. Epub 2021 May 15.

DOI:10.1016/j.aohep.2021.100359
PMID:34004366
Abstract

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions worldwide. Collectively, Latin American countries have some of the highest obesity rates in the world and the fastest-growing prevalence of type 2 diabetes mellitus (T2DM). Since obesity and T2DM are intrinsically linked with NAFLD, epidemiological projections are worrisome. In addition to this adverse epidemiological setting, the region of Latin America faces unique challenges and obstacles to addressing the growing burden of NAFLD. In this article, on the occasion of the International NASH Day on June 10, 2021, we describe the main challenges and opportunities to improve care of people living with NAFLD in Latin America. Among the major challenges to be tackled are: lack of disease awareness, limited educational opportunities for healthcare personnel and general public, health system fragmentation, and lack of effective strategies for the prevention and effective treatment of NAFLD and common comorbidities, namely obesity and T2DM. Wide dissemination of current concepts on NAFLD, and extensive collaboration between scientific societies, governments, non-governmental organizations, pharmaceutical industry, and other stakeholders is urgently needed to advance the NAFLD public health policies agenda that allows us to address this disease with a whole of society approach.

摘要

非酒精性脂肪性肝病(NAFLD)在全球范围内呈流行趋势。拉丁美洲国家的肥胖率居全球前列,2 型糖尿病(T2DM)的患病率增长最快。由于肥胖和 T2DM 与 NAFLD 密切相关,因此流行病学预测令人担忧。除了这种不利的流行病学情况外,拉丁美洲地区在应对日益增长的 NAFLD 负担方面还面临着独特的挑战和障碍。在这篇文章中,正值 2021 年 6 月 10 日的国际 NASH 日,我们描述了改善拉丁美洲地区 NAFLD 患者护理的主要挑战和机遇。需要解决的主要挑战包括:对疾病认识不足,医疗保健人员和公众的教育机会有限,卫生系统碎片化,以及缺乏有效的预防和治疗 NAFLD 及常见合并症(肥胖和 T2DM)的策略。迫切需要广泛传播当前关于 NAFLD 的概念,并加强科学协会、政府、非政府组织、制药行业和其他利益攸关方之间的合作,以推进 NAFLD 公共卫生政策议程,使我们能够采取全社会方法来应对这一疾病。

相似文献

1
NAFLD: Challenges and opportunities to address the public health problem in Latin America.非酒精性脂肪性肝病:解决拉丁美洲公共卫生问题的挑战与机遇。
Ann Hepatol. 2021 Sep-Oct;24:100359. doi: 10.1016/j.aohep.2021.100359. Epub 2021 May 15.
2
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
3
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
4
Non-alcoholic fatty liver disease: A growing public health problem in Turkey.非酒精性脂肪性肝病:土耳其日益严重的公共卫生问题。
Turk J Gastroenterol. 2019 Oct;30(10):865-871. doi: 10.5152/tjg.2019.18045.
5
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.全球 2 型糖尿病患者非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学:系统评价和荟萃分析。
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
6
Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world.综述文章:全球非酒精性脂肪性肝病的流行病学负担。
Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26.
7
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中;新的问题出现了。
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
8
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.拉丁美洲肝脏研究学会(ALEH)非酒精性脂肪性肝病诊治实践指南。
Ann Hepatol. 2020 Nov-Dec;19(6):674-690. doi: 10.1016/j.aohep.2020.09.006. Epub 2020 Oct 5.
9
Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis.拉丁美洲非酒精性脂肪性肝病的患病率:系统评价和荟萃分析。
Ann Hepatol. 2022 Nov-Dec;27(6):100706. doi: 10.1016/j.aohep.2022.100706. Epub 2022 Apr 13.
10
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?全球非酒精性脂肪性肝病政策审查与准备指数:各国是否准备好应对这一无声的公共卫生挑战?
J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.

引用本文的文献

1
Inter- and intra-observer agreement in ultrasound diagnosis of steatotic liver disease: implications for screening in resource-limited settings.超声诊断脂肪性肝病的观察者间和观察者内一致性:对资源有限环境下筛查的意义。
Sci Rep. 2025 Aug 14;15(1):29819. doi: 10.1038/s41598-025-07862-1.
2
INCIDENTAL HEPATIC STEATOSIS IDENTIFIED ON ULTRASOUND IN PATIENTS UNDERGOING CHOLECYSTECTOMY: HIGH PREVALENCE AND INSUFFICIENT INVESTIGATIVE AND CLINICAL MANAGEMENT.胆囊切除术患者超声检查发现的偶然肝脂肪变性:高患病率及调查和临床管理不足
Arq Gastroenterol. 2025 May 2;62:e24118. doi: 10.1590/S0004-2803.24612024-118. eCollection 2025.
3
MetALD: New Perspectives on an Old Overlooked Disease.
线粒体酒精性肝病:一种被长期忽视的古老疾病的新视角
Liver Int. 2025 May;45(5):e70017. doi: 10.1111/liv.70017.
4
Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.1990年至2021年全球、区域和国家层面非酒精性脂肪性肝炎相关肝癌的负担。
Front Nutr. 2025 Jan 27;12:1510563. doi: 10.3389/fnut.2025.1510563. eCollection 2025.
5
Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD).生酮饮食对非酒精性脂肪性肝病(NAFLD/MAFLD)的有益作用。
J Clin Med. 2024 Aug 17;13(16):4857. doi: 10.3390/jcm13164857.
6
Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions.探索叶黄素在脂肪性肝病中的治疗潜力:机制见解与未来方向。
Front Pharmacol. 2024 Jun 24;15:1406784. doi: 10.3389/fphar.2024.1406784. eCollection 2024.
7
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.酒精性肝病与非酒精性脂肪性肝病的交集。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):764-783. doi: 10.1038/s41575-023-00822-y. Epub 2023 Aug 15.
8
Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective.从临床和公共卫生角度看非酒精性脂肪性肝病中的肝细胞癌
Hepatobiliary Surg Nutr. 2022 Oct;11(5):755-758. doi: 10.21037/hbsn-22-386.
9
Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990-2019: A joinpoint and age-period-cohort analysis.1990 - 2019年全球非酒精性脂肪性肝病发病率的长期趋势:一项Joinpoint和年龄-时期-队列分析
Front Cardiovasc Med. 2022 Sep 12;9:891963. doi: 10.3389/fcvm.2022.891963. eCollection 2022.
10
Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement.拉丁美洲的肝脏疾病:现状、未满足的需求及改善机遇
Curr Treat Options Gastroenterol. 2022;20(3):261-278. doi: 10.1007/s11938-022-00382-1. Epub 2022 Jun 16.